#EIB #Netherlands #Xeltis #aXess #Eindhoven

Xeltis Secures Significant Financing to Propel aXess to Market

Xeltis, renowned for its innovative developments in vascular implants, recently announced a substantial financing round of nearly €50 million. This funding, primarily sourced from the European Investment Bank (EIB) and long-standing investors, will significantly accelerate the commercialization of aXess, a cutting-edge vascular access conduit designed to enhance hemodialysis treatment outcomes.

Overview of the Investment

The financial package includes up to €37.5 million from the EIB, structured with an initial €10 million upfront investment and the potential for an additional €27.5 million. Alongside this, existing shareholders, such as EQT Life Sciences and Invest-NL, contributed €10 million towards this initiative. The strategic funding aims to scale production capabilities, recruit vital personnel, and support the continued growth of Xeltis' product pipeline.

This investment aligns with the company’s recent success in clinical trials, showcasing the effectiveness of aXess in meeting the vascular access needs of patients undergoing hemodialysis. The pivotal EU trial demonstrated not only promising patency rates but also a significant reduction in infection prevalence and the necessity for additional interventions when compared to traditional methods of care. This breakthrough indicates that aXess has the potential to fundamentally transform patient treatment modalities.

The Journey to Commercialization

With market approvals anticipated in both Europe and the United States in 2026, Xeltis is poised to revolutionize vascular access treatments. The momentum gained from this financing will allow Xeltis to enhance its production facilities drastically, thereby ensuring a robust supply chain ready for market demands. CEO Eliane Schutte expressed deep gratitude for the strong endorsement from the EIB and existing investors, emphasizing the confidence placed in the company's vision and capabilities at such a crucial juncture.

Vice President Robert de Groot from the EIB echoed this sentiment, highlighting the importance of Xeltis' contributions to improving outcomes for patients afflicted by dialysis and cardiovascular issues. His remarks underline the EIB's commitment to fostering innovation and the advancement of medical technology that facilitates healthier futures for patients across Europe.

Looking Ahead: Continued Growth and Broader Applications

In addition to aXess, Xeltis is also advancing other products using its proprietary Endogenous Tissue Restoration (ETR) platform. This includes the coronary artery bypass conduit, Xabg, which recently reported impressive long-term outcomes in clinical trials that surpass expectations for artificial bypass solutions. These advancements present vast potential for addressing various vascular and cardiovascular diseases, further solidifying Xeltis' position as a leader in the medtech space.

As the company gears up for commercialization, the additional funds will enable the development of a comprehensive product pipeline utilizing their innovative polymer technology designed to create natural, living vessels within the body. This pioneering approach not only offers a significant improvement over current alternatives but also aims to enhance the overall quality of life for patients requiring vascular access.

Conclusion

With this recent financial boost, Xeltis stands at the forefront of a potential medical revolution. By shifting away from temporary solutions towards regenerative, living implants that restore natural vascular function, Xeltis is set to make substantial contributions to improving patient care in the arena of renal and cardiovascular treatments. As they progress towards market launch, the support from the EIB and existing stakeholders underlines a collective belief in Xeltis' vision to transform medical outcomes and enhance the health of millions.

For more information about Xeltis and its innovative solutions, visit Xeltis' official website.